EP3478270A4 - Semi-solid and viscous liquid nasal formulations of cannabinoids - Google Patents
Semi-solid and viscous liquid nasal formulations of cannabinoids Download PDFInfo
- Publication number
- EP3478270A4 EP3478270A4 EP17805945.7A EP17805945A EP3478270A4 EP 3478270 A4 EP3478270 A4 EP 3478270A4 EP 17805945 A EP17805945 A EP 17805945A EP 3478270 A4 EP3478270 A4 EP 3478270A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cannabinoids
- semi
- solid
- viscous liquid
- nasal formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930003827 cannabinoid Natural products 0.000 title 1
- 239000003557 cannabinoid Substances 0.000 title 1
- 229940065144 cannabinoids Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662344486P | 2016-06-02 | 2016-06-02 | |
US201662426403P | 2016-11-25 | 2016-11-25 | |
PCT/IB2017/000759 WO2017208072A2 (en) | 2016-06-02 | 2017-06-02 | Nasal cannabidiol compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3478270A2 EP3478270A2 (en) | 2019-05-08 |
EP3478270A4 true EP3478270A4 (en) | 2019-11-27 |
Family
ID=60478110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17805945.7A Pending EP3478270A4 (en) | 2016-06-02 | 2017-06-02 | Semi-solid and viscous liquid nasal formulations of cannabinoids |
Country Status (12)
Country | Link |
---|---|
US (1) | US20170348276A1 (en) |
EP (1) | EP3478270A4 (en) |
KR (1) | KR102433459B1 (en) |
CN (1) | CN109789090A (en) |
BR (1) | BR112018075073A2 (en) |
CA (1) | CA3026274A1 (en) |
CL (1) | CL2018003452A1 (en) |
CO (1) | CO2018013654A2 (en) |
MX (1) | MX2018014978A (en) |
TW (1) | TWI790204B (en) |
UY (1) | UY37271A (en) |
WO (1) | WO2017208072A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9907823B1 (en) | 2014-11-07 | 2018-03-06 | Eric H. Kuhrts | Water-soluble phytocannabinoid formulations |
WO2019064234A1 (en) | 2017-09-28 | 2019-04-04 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome with cannabidiol |
US20190240148A1 (en) * | 2018-02-07 | 2019-08-08 | Tarukino Holdings, Inc. | Lubricant composition and method for preparing the composition |
US20210008026A1 (en) * | 2018-03-05 | 2021-01-14 | Solva, Llc | Water-soluble phytocannabinoid formulations |
US11020357B2 (en) * | 2018-03-19 | 2021-06-01 | Alexandra Yerike | Compound for use in relief of pain and method to produce thereof |
EP3856172A4 (en) * | 2018-09-28 | 2022-10-05 | Visceral Therapeutics Inc. | Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions |
US20200170962A1 (en) * | 2018-11-30 | 2020-06-04 | F. Markus Leweke | Nasal cannabidiol compositions |
JP2022517724A (en) * | 2018-12-14 | 2022-03-10 | アセラス バイオファーマ インコーポレーテッド | Active ester derivatives of testosterone, compositions, and their use |
WO2020121260A1 (en) | 2018-12-14 | 2020-06-18 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
BR102018076973A2 (en) * | 2018-12-21 | 2020-09-15 | Entourage Participações S.A. | PHARMACEUTICAL COMPOSITION UNDERSTANDING CANNABIS EXTRACT, PHARMACEUTICAL PRODUCT, PROCESS OF PREPARATION OF SUCH COMPOSITION |
WO2020142692A1 (en) * | 2019-01-04 | 2020-07-09 | Columbia Care Llc | Topical formulations having cannabinoid |
WO2020146478A1 (en) * | 2019-01-08 | 2020-07-16 | Replennabis LLC | Cannabinoid formulations for treating alcohol hangover |
US20220110887A1 (en) * | 2019-02-08 | 2022-04-14 | Schedule 1 Therapeutics, Inc. | Compositions comprising cannabinoids and methods of use thereof |
US10993928B2 (en) * | 2019-04-26 | 2021-05-04 | Natural Extraction Systems, LLC | Compositions comprising non-crystalline forms of cannabidiol |
CN110433133A (en) * | 2019-08-19 | 2019-11-12 | 中国人民解放军军事科学院军事医学研究院 | The cannabidiol nasal formulations for treating posttraumatic stress disorder |
CA3151691A1 (en) | 2019-08-30 | 2021-03-04 | Sakso | Loaded granules, their process of production and their uses |
GB2588455B (en) * | 2019-10-25 | 2022-12-21 | Gw Res Ltd | Cannabinoid compound |
CA3163788A1 (en) * | 2019-12-06 | 2021-06-10 | JLABS Beauty LLC | Topical compositions containing rose oil and cannabidiol and methods of making and using the same |
TWI708835B (en) * | 2020-01-17 | 2020-11-01 | 和協工程股份有限公司 | Slow release type carbon-releasing gel substrate and soil treatment method |
CH717205A1 (en) * | 2020-03-11 | 2021-09-15 | Jk Holding Gmbh | Use of cannabinoids in therapy and wellness devices. |
US20210322343A1 (en) * | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
EP3984522A1 (en) * | 2020-10-19 | 2022-04-20 | Shima Khaki | Composition, device and use |
IT202100014909A1 (en) * | 2021-06-08 | 2022-12-08 | Velleja Res S R L | OILY FORMULATIONS OF CANNABINOIDS |
CN113304109A (en) * | 2021-06-08 | 2021-08-27 | 内蒙古大唐药业股份有限公司 | A flavone acetylsalicylate solid lipid nanoparticle dispersion and its preparation method |
WO2023028708A1 (en) * | 2021-09-02 | 2023-03-09 | Canopy Growth Corporation | Water-soluble cannabinoid compositions, methods of making and use |
US11471905B1 (en) | 2021-09-23 | 2022-10-18 | Apackaging Group Llc | All plastic airless pump dispenser |
EP4186490A1 (en) | 2021-11-29 | 2023-05-31 | Sanity Group GmbH | Kit for preparing a medicament, cannabinoid composition, and preparation method |
WO2023177675A1 (en) * | 2022-03-15 | 2023-09-21 | Milehigh Repro Solutions, Llc | Methods and systems to reduce injury in treated tissues |
US11666543B1 (en) * | 2022-07-05 | 2023-06-06 | Poviva Corp. | Pharmaceutical compositions and methods for treating hypertension |
WO2024010628A1 (en) * | 2022-07-05 | 2024-01-11 | Poviva Corp | Pharmaceutical compositions and methods for treating hypertension |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060639A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
WO2002064109A2 (en) * | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
GB0103638D0 (en) * | 2001-02-14 | 2001-03-28 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
KR20070118069A (en) * | 2004-12-09 | 2007-12-13 | 인시스 테라퓨틱스, 인코포레이티드 | Room-temperature stable dronabinol formulations |
CA2836405C (en) * | 2011-05-15 | 2021-09-07 | Trimel Biopharma Srl | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
-
2017
- 2017-06-02 KR KR1020187038219A patent/KR102433459B1/en active IP Right Grant
- 2017-06-02 TW TW106118333A patent/TWI790204B/en active
- 2017-06-02 WO PCT/IB2017/000759 patent/WO2017208072A2/en unknown
- 2017-06-02 EP EP17805945.7A patent/EP3478270A4/en active Pending
- 2017-06-02 CA CA3026274A patent/CA3026274A1/en active Pending
- 2017-06-02 BR BR112018075073-5A patent/BR112018075073A2/en active Search and Examination
- 2017-06-02 UY UY0001037271A patent/UY37271A/en not_active Application Discontinuation
- 2017-06-02 US US15/613,116 patent/US20170348276A1/en active Pending
- 2017-06-02 MX MX2018014978A patent/MX2018014978A/en unknown
- 2017-06-02 CN CN201780041815.6A patent/CN109789090A/en active Pending
-
2018
- 2018-12-03 CL CL2018003452A patent/CL2018003452A1/en unknown
- 2018-12-17 CO CONC2018/0013654A patent/CO2018013654A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060639A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
Also Published As
Publication number | Publication date |
---|---|
BR112018075073A2 (en) | 2019-04-30 |
CA3026274A1 (en) | 2017-12-07 |
UY37271A (en) | 2017-11-30 |
TW201801721A (en) | 2018-01-16 |
WO2017208072A2 (en) | 2017-12-07 |
US20170348276A1 (en) | 2017-12-07 |
KR102433459B1 (en) | 2022-08-17 |
KR20190034506A (en) | 2019-04-02 |
CO2018013654A2 (en) | 2019-08-30 |
CN109789090A (en) | 2019-05-21 |
EP3478270A2 (en) | 2019-05-08 |
WO2017208072A3 (en) | 2018-01-11 |
CL2018003452A1 (en) | 2019-06-21 |
TWI790204B (en) | 2023-01-21 |
MX2018014978A (en) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3478270A4 (en) | Semi-solid and viscous liquid nasal formulations of cannabinoids | |
EP3538078A4 (en) | Formulations for efficient delivery of cannabinoids | |
EP3270896A4 (en) | Preparations of cannabis emulsions and methods thereof | |
MA46466A (en) | PHARMACEUTICAL FORMULATIONS OF REDUCED VISCOSITY PROTEINS | |
EP3267964A4 (en) | Peg free stable low viscosity oil-in-water emulsion and use thereof | |
EP3352577A4 (en) | Cannabinoid compositions and methods of making | |
EP3288553A4 (en) | Combinations of cannabinoids and n-acylethanolamines | |
IL287947A (en) | Reducing viscosity of pharmaceutical formulations | |
EP3723752A4 (en) | New solid forms of cannabidiol and uses thereof | |
EP3364958A4 (en) | Modulators of sestrin-gator2 interaction and uses thereof | |
EP3265096A4 (en) | Ophthalmic compositions and methods of use therefor | |
EP3525764A4 (en) | An oral composition of extracted cannabinoids and methods of use thereof | |
EP3240854A4 (en) | Emulsions containing alkyl ether sulfates and uses thereof | |
EP3380525A4 (en) | Pharmaceutical formulations and methods of use thereof | |
GB201511397D0 (en) | Liquid of gel delivery devices | |
EP3294205A4 (en) | Dental solution dispenser and methods of use | |
EP3624589A4 (en) | Stable liquid formulations of prothioconazole | |
EP3177271A4 (en) | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof | |
PL3435986T3 (en) | New tablettable formulation of lutein and/or zeaxanthin | |
EP3400026A4 (en) | Viscosity and stability modified ultrasound gel | |
EP3700519A4 (en) | Cannabinoid compositions and methods of use therof | |
EP3337474A4 (en) | Quantitative peri-orbital application of ophthalmology drugs | |
EP3433225A4 (en) | Novel derivatives of curcuminoids and use thereof as an anticancer agent | |
EP3399974A4 (en) | Food based delivery of cannabinoids | |
GB201718468D0 (en) | Stable liquid pharmaceutical compositions of bortezomb |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181221 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191028 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/44 20170101ALI20191022BHEP Ipc: A61P 29/00 20060101ALI20191022BHEP Ipc: A61K 9/00 20060101ALI20191022BHEP Ipc: A61K 31/05 20060101ALI20191022BHEP Ipc: A61K 9/10 20060101AFI20191022BHEP Ipc: A61P 25/00 20060101ALI20191022BHEP Ipc: C07C 39/23 20060101ALI20191022BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210409 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |